Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Evaluation ViewAttendees 32
Clubs

Academic and Research Skills

Basic Science

Clinical Research

Developmental Biology

General Pediatrics

Global Neonatal & Children's Health

Neonatology
Session Type: Clubs in Convention Center

39th Annual Audrey K. Brown Kernicterus Symposium

Monday, May 6, 2024
11:30 AM – 1:00 PM ET
Location: Metro Toronto Convention Centre: 606
CE: Live CME: 1.5

Disclosure(s):
Jon F. Watchko, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Cynthia F. Bearer, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
David K. Stevenson, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Session

Description: The annual symposium will explore the mechanisms underlying the development of hazardous hyperbilirubinemia and bilirubin neurotoxicity, highlighting their clinical implications. This year’s program features two leading experts in the field. Dr. Robert D. Christensen will review the laboratory tests used in the diagnosis of neonatal hemolysis and highlight the use of end-tidal carbon monoxide (CO), corrected for ambient CO (ETCOc), measurements as a diagnostic tool. Dr. Michael Kaplan will highlight the role glucose-6-phosphate dehydrogenase (G6PD) deficiency plays in hazardous hyperbilirubinemia risk and the varied temporal patterns of postnatal hyperbilirubinemia observed in this condition. A better understanding of neonatal hemolysis and hemolytic conditions that drive the development of hazardous hyperbilirubinemia will improve clinical practice and reduce the incidence of bilirubin neurotoxicity globally.

Learning Objectives:

  • Upon completion, participants will be able to list four readily available laboratory tests that are used as biomarkers for hemolysis in the neonate.
  • Upon completion, participants will be able to describe the physiologic basis of end-tidal breath carbon monoxide (ETCO) quantification for diagnosing and quantifying hemolysis in neonates.
  • Upon completion, participants will be able to describe the various temporal patterns of hyperbilirubinemia reported in neonates with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Presentations:

  • 11:30 AM – 11:55 AM ET
    A “Gold Standard” Test for Diagnosing and Quantifying Hemolysis in Neonates and Infants

    Speaker: Robert D. Christensen, MD (he/him/his) – University of Utah School of Medicine

  • 11:55 AM – 12:20 PM ET
    Controversies in Our Understanding of Extreme Hyperbilirubinemia in G6PD-Deficient Neonates

    Speaker: Michael Kaplan, MB ChB (he/him/his) – Hebrew University, Jerusalem, Israel